Equities

Disc Medicine Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IRON:NMQ

Disc Medicine Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)64.36
  • Today's Change-2.18 / -3.28%
  • Shares traded585.18k
  • 1 Year change+18.46%
  • Beta0.8682
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 26-Feb-26
Select bar for recommendation details.
Recommendations26-Feb-26
Buy5
Outperform8
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 12 analysts offering 12 month price targets for Disc Medicine Inc have a median target of 100.00, with a high estimate of 128.00 and a low estimate of 75.00. The median estimate represents a 55.38% increase from the last price of 64.36.
High98.9%128.00
Med55.4%100.00
Low16.5%75.00

Earnings history & estimates in USD

On Feb 26, 2026, Disc Medicine Inc reported 4th quarter 2025 losses of -1.64 per share. This result exceeded the -1.74 consensus loss of the 12 analysts covering the company and under-performed last year's 4th quarter results by 67.35%.
The next earnings announcement is expected on May 05, 2026.
Average growth rate-15.92%
Disc Medicine Inc reported annual 2025 losses of -6.01 per share on Feb 26, 2026.
Average growth rate-32.07%
More ▼

Revenue history & estimates in USD

Disc Medicine Inc did not report revenues for the 4th quarter 2025. However, during the 4th quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Disc Medicine Inc did not report revenues for the full year 2025. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.